Karl Bordeau, Morgan Michalet, Aïcha Keskes, Simon Valdenaire, Pierre Debuire, Marie Cantaloube, Morgane Cabaillé, Fabienne Portales, Roxana Draghici, Marc Ychou, Eric Assenat, Thibault Mazard, Emmanuelle Samalin, Ludovic Gauthier, Pierre-Emmanuel Colombo, Sebastien Carrere, François-Régis Souche, Norbert Aillères, Pascal Fenoglietto, David Azria, Olivier Riou
INTRODUCTION: Stereotactic MR-guided Adaptive RadioTherapy (SMART) is a novel process to treat pancreatic tumors. We present an update of the data from our prospective registry of SMART for pancreatic tumors. MATERIALS AND METHODS: After the establishment of the SMART indication in a multidisciplinary board, we included all patients treated for pancreatic tumors. Primary endpoints were acute and late toxicities. Secondary endpoints were survival outcomes (local control, overall survival, distant metastasis free survival) and dosimetric advantages of adaptive process on targets volumes and OAR...
December 20, 2022: Cancers